Latest filing published 23 Mar 2021 for Cardiff Oncology, Inc., €8,294.
Filing timeline
BuySaleInsider track record
Closed purchases
Not enough history yet: 1 closed purchase, at least 2 are needed.
Purchases by company
Since each purchase
- -74.5%Entry US$10.14 · Close at T+365 US$2.59
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Vicki Kelemen: trading record in brief
Vicki Kelemen is a declared insider of Cardiff Oncology, Inc., with filings sourced from SEC (Form 4). We count 5 filings; the first trade dates from 23 November 2020 and the latest from 23 March 2021.
In open-market terms, that means 1 purchase worth €8,294 on one side and 1 sale worth €554k on the other. On balance, insiders were net sellers of €545k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 1 share grant and 2 option exercises. 2021 to date brings 1 purchase and no sales.
The record was last updated on 23 March 2021 with an open-market purchase (€8,294) in Cardiff Oncology, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Vicki Kelemen
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 960 shares@ US$10.311.3% of flowCommon StockSEC:0001628280-21-005343:0Canonical exit: 21 Jun 2021 (T+90)
- 70 shares0Common StockSEC:0001628280-21-000061:0
- 31 shares0Common StockSEC:0001628280-21-000061:1
- 35,321 shares@ US$2.4811.8% of flowCommon StockSEC:0001628280-20-016822:0
- 35,321 shares@ US$18.601488.2% of flowCommon StockSEC:0001628280-20-016822:1
5 of 5 declarations